Matches in SemOpenAlex for { <https://semopenalex.org/work/W2070461749> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2070461749 endingPage "166" @default.
- W2070461749 startingPage "166.2" @default.
- W2070461749 abstract "<h3>Background</h3> Renal cell carcinoma (RCC) represents only 2-3% of all cancers. Sunitinib is a standard initial therapy in advanced and metastatic renal cell carcinoma. <h3>Purpose</h3> A retrospective review was performed to assess the safety of sunitinib in RCC. <h3>Materials and methods</h3> RCC patients undergoing sunitinib treatment and follow-up for at least one month were included. Variables: sex, age, nephrectomy status, histology, risk group, metastatic sites, sunitinib starting dose, % adverse events (AEs) from Common Terminology Criteria for Adverse Events (CTCAE version 4.0), % grade 3-4 AE, % starting dose reduction, % extra week rest period and % colony stimulating factors (CSF) used for toxicity management. Statistical analysis by SPSS 18.0. <h3>Results</h3> 19 patients were analysed: 73.7% male, median age 62 years, 94.7% previously nephrectomised (78.9% radical nephrectomy and 15.8% partial nephrectomy), median time to sunitinib treatment 60.5 months. By histology, 79.0% was clear cell carcinomas. Grouped according to their risk (57.9% of patients could be assessed for risk): 15.8% were assessed as favourable, 26.3% intermediate and 15.8% unfavourable. Median metastatic sites were 3, sorted by frequency: lung 68.4%, liver 47.4%, soft tissues 26.3%, bone and pleura 21.1%, brain, skin and heart 10.5%. Starting dose of sunitinib were 68.4% 50 mg/day, 26.3% 37.5 mg/day and 5.3% 25 mg/day administered for four consecutive weeks and followed by a two-week rest period. 100% patients reported at least one AE. The most frequent AEs were asthenia 11.6%, neutropenia or thrombocytopenia 10.7%, hypertension or diarrhoea 9.9%. Grade 3-4 events were neutropenia 4.1%, anaemia 2.5%, bleeding 1.6%, hypertension, hand-foot syndrome or diarrhoea <1.0%. In addition, one case of toxic hepatitis and a cerebral oedema event were reported. Median cycles sunitinib received were 4.3. Toxicity management consisted of dose reduction 38.4%, extra week rest period 57.6%, no patients required CSF as filgrastim or epoetin α. <h3>Conclusions</h3> With sunitinib, adverse events such as hematologic toxicity, asthenia, hypertension and gastrointestinal events were common. Toxicity management included dose reduction or additional rest period." @default.
- W2070461749 created "2016-06-24" @default.
- W2070461749 creator A5001652409 @default.
- W2070461749 creator A5021026564 @default.
- W2070461749 creator A5066395654 @default.
- W2070461749 creator A5070721023 @default.
- W2070461749 creator A5072414784 @default.
- W2070461749 creator A5089657312 @default.
- W2070461749 date "2012-03-12" @default.
- W2070461749 modified "2023-09-27" @default.
- W2070461749 title "Safety of sunitinib in renal cell carcinoma" @default.
- W2070461749 doi "https://doi.org/10.1136/ejhpharm-2012-000074.215" @default.
- W2070461749 hasPublicationYear "2012" @default.
- W2070461749 type Work @default.
- W2070461749 sameAs 2070461749 @default.
- W2070461749 citedByCount "1" @default.
- W2070461749 countsByYear W20704617492013 @default.
- W2070461749 crossrefType "journal-article" @default.
- W2070461749 hasAuthorship W2070461749A5001652409 @default.
- W2070461749 hasAuthorship W2070461749A5021026564 @default.
- W2070461749 hasAuthorship W2070461749A5066395654 @default.
- W2070461749 hasAuthorship W2070461749A5070721023 @default.
- W2070461749 hasAuthorship W2070461749A5072414784 @default.
- W2070461749 hasAuthorship W2070461749A5089657312 @default.
- W2070461749 hasConcept C126322002 @default.
- W2070461749 hasConcept C126894567 @default.
- W2070461749 hasConcept C141071460 @default.
- W2070461749 hasConcept C197934379 @default.
- W2070461749 hasConcept C2777472916 @default.
- W2070461749 hasConcept C2777793932 @default.
- W2070461749 hasConcept C2779490328 @default.
- W2070461749 hasConcept C2780091579 @default.
- W2070461749 hasConcept C2780227381 @default.
- W2070461749 hasConcept C71924100 @default.
- W2070461749 hasConceptScore W2070461749C126322002 @default.
- W2070461749 hasConceptScore W2070461749C126894567 @default.
- W2070461749 hasConceptScore W2070461749C141071460 @default.
- W2070461749 hasConceptScore W2070461749C197934379 @default.
- W2070461749 hasConceptScore W2070461749C2777472916 @default.
- W2070461749 hasConceptScore W2070461749C2777793932 @default.
- W2070461749 hasConceptScore W2070461749C2779490328 @default.
- W2070461749 hasConceptScore W2070461749C2780091579 @default.
- W2070461749 hasConceptScore W2070461749C2780227381 @default.
- W2070461749 hasConceptScore W2070461749C71924100 @default.
- W2070461749 hasIssue "2" @default.
- W2070461749 hasLocation W20704617491 @default.
- W2070461749 hasOpenAccess W2070461749 @default.
- W2070461749 hasPrimaryLocation W20704617491 @default.
- W2070461749 hasRelatedWork W2070461749 @default.
- W2070461749 hasRelatedWork W2081371466 @default.
- W2070461749 hasRelatedWork W2286005466 @default.
- W2070461749 hasRelatedWork W2314142019 @default.
- W2070461749 hasRelatedWork W2397703782 @default.
- W2070461749 hasRelatedWork W2412903152 @default.
- W2070461749 hasRelatedWork W2586600986 @default.
- W2070461749 hasRelatedWork W2767512028 @default.
- W2070461749 hasRelatedWork W2928025315 @default.
- W2070461749 hasRelatedWork W2971476881 @default.
- W2070461749 hasVolume "19" @default.
- W2070461749 isParatext "false" @default.
- W2070461749 isRetracted "false" @default.
- W2070461749 magId "2070461749" @default.
- W2070461749 workType "article" @default.